Innohep (Tinzaparin Sodium)

Tinzaparin sodium, a low molecular weight heparin, is used to prevent and treat thromboembolic disorders.

• Prophylaxis of deep vein thrombosis in surgical patients: prevents clot formation after surgery.
• Treatment of acute deep vein thrombosis: facilitates clot resolution and reduces recurrence.
• Treatment and secondary prevention of pulmonary embolism: limits embolic events and supports recovery.
• Prevention of clotting in hemodialysis circuits: maintains circuit patency during dialysis sessions.

• Tinzaparin sodium binds to antithrombin III, markedly enhancing its ability to inactivate factor Xa and, to a lesser extent, factor IIa (thrombin). By accelerating the inhibition of these key coagulation enzymes, the drug reduces thrombin generation and fibrin formation, thereby preventing the development and propagation of pathological blood clots. The selective inhibition of factor Xa provides a predictable anticoagulant response with a lower risk of platelet interaction compared with unfractionated heparin.

Tinzaparin sodium may cause a range of adverse reactions, most of which are related to its anticoagulant activity.

Common Side Effects

• Injection site pain or erythema: mild discomfort at the injection site.
• Bruising or hematoma: localized bleeding under the skin.
• Minor bleeding: such as gum or nosebleeds.
• Transient thrombocytopenia: mild decrease in platelet count.

Serious or Rare Side Effects

• Major bleeding: gastrointestinal or intracranial hemorrhage.
• Heparin‑induced thrombocytopenia (HIT): immune‑mediated platelet activation.
• Spinal or epidural hematoma: bleeding in the spinal canal after neuraxial procedures.
• Severe allergic reaction: anaphylaxis or urticaria.

When using Tinzaparin sodium, clinicians should consider several safety measures to minimize bleeding risk and other complications.

• Renal impairment: adjust dose or monitor anti‑Xa levels in patients with reduced kidney function.
• Pregnancy: category B, use only when benefit outweighs potential risk to the fetus.
• Concomitant anticoagulants: avoid or closely monitor when combined with warfarin, DOACs or other heparins.
• Surgical or invasive procedures: discontinue before major surgery to reduce bleeding risk.
• Platelet monitoring: check platelet counts regularly to detect heparin‑induced thrombocytopenia.
• Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Tinzaparin sodium can interact with other medicines that affect haemostasis, requiring careful management.

Major Interactions (Avoid)

• Other anticoagulants (e.g., warfarin, direct oral anticoagulants): additive bleeding risk.
• Thrombolytic agents (e.g., alteplase): increased risk of severe hemorrhage.
• High‑dose antiplatelet drugs (e.g., clopidogrel): heightened bleeding potential.

Moderate Interactions (Monitor Closely)

• Nonsteroidal anti‑inflammatory drugs (NSAIDs): may exacerbate minor bleeding.
• Selective serotonin reuptake inhibitors (SSRIs): potential for increased mucosal bleeding.
• ACE inhibitors: monitor for rare reports of enhanced anticoagulant effect.